NeuroSense Therapeutics Ltd. (NRSNW)
| Market Cap | 5.77M -76.8% |
| Revenue (ttm) | n/a |
| Net Income | -11.13M |
| EPS | -8.73 |
| Shares Out | 1.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 0.0103 |
| Day's Range | n/a |
| 52-Week Range | 0.0011 - 0.5445 |
| Beta | 1.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 25, 2026 |
About NRSNW
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical stu... [Read more]
News
NeuroSense secures Nasdaq hearing date as PrimeC approaches milestones
NeuroSense (NRSN) announced that its hearing before the Nasdaq Hearings Panel is scheduled for November 10, following its appeal of the October 1 Staff Delisting Determination. The appeal stays the…
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained Near-term catalysts include a New Drug Submission to Health Canada targeted for December ...
NeuroSense downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded NeuroSense (NRSN) to Neutral from Buy with a $3.50 price target The firm cites the company’s PrimeC Phase 3 study delay for the downgrade. First enrollment is…
NeuroSense Provides Update on Nasdaq Listing Compliance
Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value...
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mas...
NeuroSense target adjusted to $52 from $8 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on NeuroSense (NRSN) to $52 from $8 and keeps a Buy rating on the shares following the 1:20 reverse split. The firm says…
NeuroSense Provides Business Update and Progress for the First Half of 2026
CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd.
Neurosense Therapeutics Ltd trading halted, news pending
19:50 EDT Neurosense (NRSN) Therapeutics Ltd trading halted, news pending
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
Company presentation on Tuesday, September 15 at 4:30 p.m. ET Management will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mass.
NeuroSense initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of NeuroSense (NRSN) with a Buy rating and $8 price target NeuroSense is a late clinical-stage biopharmaceutical company developing PrimeC, a novel, extended-release...
NeuroSense announces redesigned development plan for PrimeC
NeuroSense (NRSN) Therapeutics announced a redesigned development plan for PrimeC in amyotrophic lateral sclerosis, structured to reach a potential path for regulatory submission and approval faster a...
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's...
NeuroSense Issues CEO Letter to Shareholders
CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense sees December 2026 as filing date for NDS for PrimeC
NeuroSense (NRSN) Therapeutics announced that it is targeting December 2026 for the filing of a New Drug Submission with Health Canada for PrimeC, its lead therapeutic candidate for amyotrophic latera...
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
Final meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submission CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Registration statement: Registration filing
NeuroSense Therapeutics filed a registration statement on July 30, 2026, providing details about a securities offering with the SEC.
NeuroSense Therapeutics Slides: Corporate presentation
NeuroSense Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 28, 2026.
NeuroSense to file NDS to Health Canada for PrimeC for treatment of ALS
NeuroSense (NRSN) Therapeutics announced it intends to proceed with the filing of a New Drug Submission, or NDS, to Health Canada for PrimeC for the treatment of amyotrophic lateral sclerosis,…
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-p...
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward CAMBRIDGE, Mass.
NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint
NeuroSense (NRSN) Therapeutics announced that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis has successfully met its primary efficacy endpoint, demonstrating a statistically s...
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS TDP-43 pathology is present in more than 97% of ALS cases and...
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement Findings ...
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense granted South Korean patent covering PrimeC composition for ALS
NeuroSense (NRSN) Therapeutics announced that the Korean Intellectual Property Office has issued Korean Patent Number 10-2969898 covering the composition of PrimeC, the company’s lead drug candidate f...